4
Orphan Designations
0 approved, 4 designated
0
FDA Approvals
0
Active Trials
4
Rare Diseases
across 7 areas
0
News (30d)
Quiet
Anavex Life Sciences Corp. is a company with 4 orphan drug designations across 4 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| Rett syndrome | (2,2-diphenyl-tetrahydro-furan-3-yl-methyl)-dimethylamine hydrochloride | Des.TrialAppr. |
| fragile X syndrome | blarcamesine | Des.TrialAppr. |
| frontotemporal dementia | 1-(2,8-Dimethyl-1-thia-3,8-diazaspiro[4.5]dec-3-yl)-3-(1H-indol-3-yl)propan-1-one | Des.TrialAppr. |
| infantile spasms | tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
5
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
5
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
0
affecting portfolio